Attiva gli avvisi di lavoro via e-mail!
A leading biopharmaceutical company based in Italy is seeking a Senior Director, Clinical Program Lead. This role will oversee the management of clinical trials and cross-functional teams focused on oncology. The ideal candidate will have over 10 years of experience in drug development and a proven track record of managing complex studies. You will be integral in driving clinical operations and ensuring compliance with regulatory standards.
Join to apply for the Senior Director, Clinical Program Lead role at Menarini Stemline
Join to apply for the Senior Director, Clinical Program Lead role at Menarini Stemline
Overview
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
Overview
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).
Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.
Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.
Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.
Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA / CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1 / HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.
In 2022, the company launched the CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.
Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.
Responsibilities
Matrix leader of cross-functional Clinical Program Team responsible for operation for assigned clinical program(s). Key accountability includes successful conduct of clinical trials consistent with applicable regulations, guidelines, and procedures, as well as managing clinical project timelines, budgets, deliverables, communications and serves as main point of contact for functional issues, including any CRO / vendor performance issues and Clinical Program Team resource issues. Also may serve as the line manager of junior members of the Clinical Operations team (CTA, CRA, CPM).
Reporting to the Vice President of Clinical Operations, this role will be responsible for the clinical program management deliverables of assigned study(ies), in accordance with the agreed upon timelines, budget, and quality standards.
Qualifications
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.
Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.
Please note this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.
Salary Range : $235,000-$290,000
Seniority level
Seniority level
Director
Employment type
Employment type
Full-time
Job function
Job function
Research, Analyst, and Information Technology
Industries
Biotechnology
Referrals increase your chances of interviewing at Menarini Stemline by 2x
Get notified about new Clinical Program Director jobs in United States .
Director, Clinical Site Monitoring Oversight
United States $215,000.00-$235,000.00 1 week ago
United States $260,000.00-$300,000.00 1 week ago
New Hampshire, United States $140,000.00-$145,000.00 5 days ago
Director Clinical Development Operations
Connecticut, United States $140,000.00-$145,000.00 5 days ago
United States $170,000.00-$205,000.00 2 months ago
California, United States $220,000.00-$260,000.00 1 week ago
United States $180,000.00-$220,000.00 2 weeks ago
North Carolina, United States $140,000.00-$145,000.00 5 days ago
Texas, United States $140,000.00-$145,000.00 5 days ago
United States $150,000.00-$180,000.00 5 days ago
Director, Virtual Clinical Operations (Remote)
Director, Clinical Operations (Medical Affairs)
United States $204,000.00-$255,000.00 1 day ago
Director, Clinical Operations (Sponsor Side)
Director, Clinical Operations Transformation
United States $25,000.00-$190,000.00 6 days ago
Florida, United States $140,000.00-$145,000.00 5 days ago
Georgia, United States $140,000.00-$145,000.00 5 days ago
United States $150,000.00-$180,000.00 2 weeks ago
Nashville, TN $100,000.00-$110,000.00 1 month ago
Associate Clinical Quality Director - Client Launch
United States $200,000.00-$250,000.00 2 weeks ago
Senior Director / Director, Clinical Science
Director, Clinical Development Operations
United States $181,000.00-$216,000.00 2 weeks ago
United States $130,000.00-$145,000.00 2 weeks ago
United States $200,000.00-$230,000.00 5 days ago
United States $140,000.00-$170,000.00 3 weeks ago
Director, Clinical Site Monitoring Oversight
United States $215,000.00-$235,000.00 1 day ago
United States $195,000.00-$240,000.00 6 days ago
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
J-18808-Ljbffr